Results 21 to 30 of about 20,388,994 (310)
The Relationship Between Hepatic Activity Index and Serum Tumor Necrosis Factor Alpha Levels in Patients with Chronic Active Hepatitis-B and Chronic Active Hepatitis-C
Medicine Science, 2015 In the present study, we investigated the relationship between serum TNF-α levels and hepatic activity in liver biopsies of chronic hepatitis B and C patients.The study was performed on 30 chronic hepatitis B patients, 25 chronic hepatitis C ...Yilmaz Bilgic, Murat Harputluoglu, Bulent Yaprak, Mehmet Burak Dal, Mehmet Bugra Bozan, Abdurrahman Sahin, Fatih Mehmet Yazar, Yasir Furkan Cagin, Nihat Okcu +8 moredoaj +1 more sourceRetreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C [PDF]
, 2000 Background/Aims: Combination therapy with interferon-alpha (IFN-alpha) plus ribavirin is more efficacious than IFN-alpha monotherapy in previously untreated patients with chronic hepatitis C and patients with IFN-alpha relapse.Leifeld, Ludger, Spengler, Ulrich, Hoffmann, Robert M., Berg, Thomas, Hopf, Uwe, Pape, Gerd R., Teuber, Gerlinde, Lafrenz, Michael, Zeuzem, Stefan, Gerd R. Pape, Stefan Zeuzem, Ludger Leifeld, Ulrich Spengler, Robert M. Hoffmann, Michael Lafrenz, Uwe Hopf, Gerlinde Teuber, Thomas Berg +17 morecore +1 more sourceBicyclol for chronic hepatitis C
Cochrane Database of Systematic Reviews, 2007 Bicyclol is a novel synthetic 'anti-hepatitis' drug, used in China for chronic hepatitis C. Until now, systematic reviews on bicyclol therapy have not been performed.To study the benefits and harms of bicyclol for patients with chronic hepatitis C.We searched The Cochrane Hepato-Biliary Group Controlled Trials Register (July 2005), the Cochrane Central Yang, Xiaoyan, Zhuo, Qi, Wu, Taixiang, Liu, Guan Jian +3 moreopenaire +2 more sourcesIL28B, HLA-C, and KIR variants additively predict response to therapy in chronic Hepatitis C virus infection in a European cohort: A cross-sectional study [PDF]
, 2011 Background
To date, drug response genes have not proved as useful in clinical practice as was anticipated at the start of the genomic era. An exception is in the treatment of chronic hepatitis C virus (HCV) genotype 1 infection with pegylated interferon-Hellard, M, Powell, Elizabeth, Ahlenstiel, G., Smedile, Antonina, Bassendine, Margaret, Hammond, E., O'Connor, Kate S, Armstrong, Nicola J, Stewart, Graeme J, Müller Tobias, Silvana Gaudieri, Mallal Simon, Armstrong Nicola J., Powell Elizabeth, Graeme J Stewart, Bassendine, M, Abate, ML, Jacob Nattermann, Irving, WL, Ahlenstiel, G, Simon Mallal, Negro, F, Stewart, Graeme J., Suppiah, Vijayaprakash, Matthews, G, Suppiah Vijayaprakash, Gaudieri Silvana, Bochud Pierre-Yves, null null, Nattermann, J, Vijayaprakash Suppiah, Hammond, Emma, Graeme J. Stewart, Hellard Margaret, Bochud, P-Y, Mallal, S., Negro, F., Ahlenstiel, Golo (R18999), O'Connor, KS, Smedile, A, Booth, DR, Powell, E, George Jacob, Gaudieri, S., Negro Francesco, Pierre-Yves Bochud, Irving, W.L., David Dunn, Abate, Maria L., Dore Gregory J., Hellard, M., International Hepatitis C Genetics Consortium (IHCGC), Spengler, U., William L Irving, Dunn David, David Sheridan, Riordan Stephen, Berg Thomas, Dunn, D.S., Stewart Graeme J., Mathews, Gail, Weltman, Martin, Ulrich Spengler, Nattermann Jacob, Mallai, Simon, Dunn, D, Francesco Negro, Berg, Thomas, for the International Hepatitis C Genetics Consortium (IHCGC), Gregory J. Dore, Sheridan, D, Abate Maria Lorena, Jacob George, Nicola J Armstrong, Matthews Gail, Mallal, S, Matthews, Gail, Booth, David R, Dore, G.J., Müller, T., Kate S O'Connor, Armstrong, Nicola J., Dore, Gregory J, Gail Matthews, Spengler Ulrich, Müller, T, Booth, David R., Berg, T., Irving, William L., Spengler, U, Booth, D.R., Spengler, Ulrich, Suppiah, V, Powell, E., Martin Weltman, Emma Hammond, Dunn, David, Thomas Berg, Suppiah, Vijay, Matthews, G., Abate, Maria Lorena, Bassendine, M., Berg, T, Riordan, Stephen, Hammond, E, Muller, Tobias, Ahlenstiel, Golo, Nattermann, J., Sheridan David, Smedile Antonina, Kate S. O'Connor, Mallal, Simon, Sheridan, D., Hammond Emma, David R. Booth, Irving William L., Stewart, GJ, Maria Lorena Abate, O'Connor, Kate S., Antonina Smedile, Golo Ahlenstiel, Armstrong, N.J., Margaret Hellard, Dore, GJ, O'Connor Kate S., Gaudieri, S, Hellard, Margaret, David R Booth, Weltman Martin, Riordan, S, Irving, William L, Margaret Bassendine, Tobias Müller, Armstrong, NJ, Weltman, M., Bassendine Margaret, Booth David R., Elizabeth Powell, Smedile, A., William L. Irving, Dore, Gregory J., Stephen Riordan, Weltman, M, Sheridan, David, Negro, Francesco, Bochud, PY, Riordan, S., Bochud, Pierre-Yves, Gregory J Dore, O'Connor, K.S., George, J, Nicola J. Armstrong, Suppiah, V., Stewart, G.J., Ahlenstiel Golo, George, J., George, Jacob, Nattermann, Jacob, Abate, M.L., Gaudieri, Silvana +159 morecore +1 more sourceThe Association between Helicobacter pylori Infection and Chronic Hepatitis C: A Meta-Analysis and Trial Sequential Analysis
Gastroenterology Research and Practice, 2016 Purpose. Helicobacter pylori is a common gastric disease-inducing pathogen. Although an increasing number of recent studies have shown that H. pylori is a risk factor for liver disease, the potential association between H.Juan Wang, Wen-Ting Li, Yi-Xiang Zheng, Shu-Shan Zhao, Ning Li, Yan Huang, Rong-Rong Zhou, Ze-Bing Huang, Xue-Gong Fan +8 moredoaj +1 more sourceChronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment
Journal of the Formosan Medical Association, 2021 Background/Purpose: Effective antiviral-therapy can reduce the risk of liver cirrhosis related hepatocellular carcinoma in patients with chronic hepatitis B and hepatitis C. Yet, the difference of hepatocellular carcinoma development in chronic hepatitis Ming-Tsung Lin, Kuo-Chin Chang, Yi-Hao Yen, Ming-Chao Tsai, Chien-Hung Chen, Jing-Houng Wang, Chang-Chun Hsiao, Yueh-Hsia Chiu, Tsung-Hui Hu +8 moredoaj +1 more sourceEvidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection [PDF]
, 2006 Cellular immune responses are an important correlate of hepatitis C virus (HCV) infection outcome. These responses are governed by the host's human leukocyte antigen (HLA) type, and HLA-restricted viral escape mutants are a critical aspect of this host ...Cheng, Wendy, Battegay, Manuel, E. Freitas, Weber, R., Furrer, H., Jeffrey, G., James, Ian, Park, Lawrence P, Swiss HIV Cohort Study,, G. Jeffrey, Battegay, M., Jeffrey, Gary, Herrmann, S., James, I., Weber, R., Battegay, M., Chapman, R., S. Herrmann, Furrer, Hansjakob, Telenti, Amalio, Freitas, E., Telenti, A., Lucas, M., M. Lucas, null null, I. James, Weber, Rainer, Telenti, A., Lucas, M., Freitas, Elizabeth, H. Furrer, Cheng, W., Jeffrey, G., Gaudieri, S., S. A. Mallal, Park, P., Freitas, E., Cheng, W., K. Pfafferott, Pfafferott, K., S. Gaudieri, R. Weber, Naidoo, Kiloshni, A. Rauch, Pfafferott, K., Mallal, Simon A, L. P. Park, Rauch, A., Chapman, R., A. Telenti, Pfafferott, Katja, R. Chapman, Lucas, Michaela, M. Battegay, Park, L.P., Naidoo, K., Herrmann, Susan, K. Naidoo, Furrer, H., Rauch, Andri, Park, L. P., W. Cheng, Herrmann, S., Naidoo, K., Chapman, Russell, Rauch, A., Mallal, S.A., Gaudieri, S., Mallal, S. A., James, I., Gaudieri, Silvana +70 morecore +1 more sourceExcellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland
Swiss Medical Weekly, 2018
BACKGROUND
The introduction of direct acting antivirals (DAAs) for the therapy of chronic hepatitis C (CHC) has revolutionised treatment and marks a paradigm shift in the approach to this disease, rendering interferon-based therapies obsolete.Jacqueline A. Bachofner, Piero V. Valli, Irina Bergamin, Arne Kröger, Patrizia Künzler, Adriana Baserga, Dominique L. Braun, Burkhardt Seifert, Anja Moncsek, Jan Fehr, David Semela, Lorenzo Magenta, Beat Müllhaupt, Benedetta Terziroli Beretta-Piccoli, Joachim C. Mertens, the Swiss Hepatitis C Cohort Study +15 moredoaj +1 more source
